MTRAC issued an updated Commissioning Support guidance in August 2014. The review covers Avanafil (Spedra®).
This Commissioning Guidance (PDF) is an update to the review published in June.
This update still recommends restricted prescribing in primary care within the existing regulations imposed by the Department of Health for prescribing treatments for erectile dysfunction. It also highlights the availability of generic and off-patent formulations of other PDE-5 inhibitors.
Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.